Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Antidepressant

or Cathinone

or [[:Category:Bowel_preparation_agents|Bowel preparation agent]]

Use the filters below to narrow your results.

3-MMC (1) · Agomelatine (1) · Amoxapine (1) · Butylone (1) · Cathinone (1) · Clomipramine (1) · Desipramine (1) · Duloxetine (1) · Ephylone (1) · Ethcathinone (1) · Ethylone (1) · Hexedrone (1) · Imipramine (1) · Isocarboxazid (1) · Levomilnacipran (1) · Maprotiline (1) · Mephedrone (1) · Methcathinone (1) · Methylone (1) · Mexedrone (1) · Milnacipran (1) · Moclobemide (1) · N-Ethylhexedrone (1) · N-Ethylpentedrone (1) · Nefazodone (1) · Pentedrone (1) · Phenelzine (1) · Polyethylene glycol 3350 (PEG 3350) (1) · Polyethylene glycol 3350 with electrolytes (1) · Protriptyline (1) · Reboxetine (1) · Sertraline (1) · Tianeptine (1) · Tranylcypromine (1) · Trimipramine (1)

Cathinone analogue; monoamine reuptake inhibitor (2) · Irreversible non-selective MAO inhibitor (3) · Melatonin receptor agonist; 5-HT2C antagonist (1) · Monoamine releasing agent (4) · Monoamine releasing agent; active ingredient in khat (1) · Mu-opioid agonist; modulates glutamate AMPA receptors (1) · Norepinephrine and dopamine releasing agent (1) · Norepinephrine/dopamine releasing agent (1) · Norepinephrine/dopamine reuptake inhibitor (1) · Potent serotonin reuptake inhibitor; also NRI (1) · Reversible inhibitor of MAO-A (1) · Selective norepinephrine reuptake inhibitor (3) · Serotonin and norepinephrine reuptake inhibitor (3) · Serotonin releasing agent; monoamine reuptake inhibitor (1) · Serotonin reuptake inhibitor and 5-HT2A antagonist (1) · Serotonin/norepinephrine/dopamine releasing agent (3) · Serotonin–norepinephrine reuptake inhibition (balanced) (1) · Serotonin–norepinephrine reuptake inhibitor (2) · TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) · Weak SRI; primarily H1/D2/alpha antagonist (1) · '"`UNIQ--vote-00000054-QINU`"' The clinical efficacy endpoint is adequate visualization at colonoscopy, scored by the Boston Bowel Preparation Scale'"`UNIQ--ref-00000055-QINU`"'. (1) · '"`UNIQ--vote-0000132D-QINU`"' Electrolyte-balanced bowel-prep formulations are designed to be iso-osmotic with plasma so the volume passes through without net fluid or electrolyte shifts, the basis of their safety for whole-bowel evacuation. (1)

None (32) · Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) · '"`UNIQ--vote-00000056-QINU`"', '"`UNIQ--vote-00000057-QINU`"' (1) · '"`UNIQ--vote-0000132E-QINU`"', '"`UNIQ--vote-0000132F-QINU`"', '"`UNIQ--vote-00001330-QINU`"' (1)

None (32) · 25 mg (1) · 4 L oral solution (GoLYTELY-class) split-dose: 2 L evening before, 2 L morning of procedure; low-volume products (MoviPrep, Plenvu) use 1-2 L with required clear-fluid intake (1) · Constipation: 17 g (one capful) PO daily dissolved in 4-8 oz fluid; bowel prep: 4 L of PEG-electrolyte solution split-dose evening before and morning of procedure (1)

None (32) · 17 g (OTC) and 14 g (Rx) powder packets; 238, 510, 527 g bottles; PEG-electrolyte preparations 4 L (GoLYTELY, NuLYTELY) (1) · 25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1) · Powder for oral solution in 4 L jugs (PEG 3350 ~236 g + NaCl, NaHCO3, KCl, Na2SO4) and low-volume packets (1)

None (32) · 200 mg/d (1) · 4 L per procedure (standard-volume products) (1) · Indication-specific; bowel prep regimens reach 4 L cumulative (1)

None (31) · Oral (4)

None (31) · Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) · Constipation: 1-3 days; bowel prep: 1-3 hours after starting (1) · First bowel movement within 1-2 hours (1) · Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1)

None (31) · 4-6 hours (1) · Chronic daily dosing (1) · Hours (1) · Long (1)

None (31) · Not absorbed (1) · Not meaningfully described (negligible systemic absorption) (1) · ~12 hours (1) · ~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1)

None (31) · <0.1% systemic absorption (PEG 3350 is too large to absorb intact) (1) · Absolute bioavailability not precisely characterized; food modestly increases exposure (1) · Negligible (not absorbed)'"`UNIQ--ref-00000058-QINU`"' (1) · ~50% (highly variable) (1)

None (31) · Category C (1) · Category C'"`UNIQ--ref-0000008F-QINU`"' (1) · Generally considered safe due to minimal systemic absorption.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) · Not absorbed; generally considered acceptable when bowel prep is required<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)

None (31) · OTC (MiraLAX) and [[USLegal:Prescription only|Rx-only]] (electrolyte solutions for bowel prep) in US (1) · Rx-only (1) · Rx-only in US (1) · [[USLegal:Prescription only|Rx-only]] in US (most products; some low-volume packs OTC) (1)